Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | ADAMTS5 | Q9UNA0 | 13/20 | 0.43 |
| ▸ | MMP14 | P50281 | 9/20 | 0.42 |
| ▸ | MMP2 | P08253 | 8/20 | 0.42 |
| ▸ | MMP13 | P45452 | 3/20 | 0.42 |
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | HTR2B | P41595 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5630383 | 1.00 | RAD52 (0.46) | RAD52SLC6A2SLC6A4SLC6A3ADAMTS5 | |
| SCHEMBL5632581 | 1.00 | RAD52 (0.46) | RAD52SLC6A2SLC6A4SLC6A3ADAMTS5 | |
| Hydrochloric Acid SCHEMBL28350085 | 0.99 | RAD52 (0.48) | RAD52SLC6A2SLC6A4SLC6A3ADAMTS5 | |
| Hydrochloric Acid SCHEMBL5632260 | 0.99 | RAD52 (0.48) | RAD52SLC6A2SLC6A4SLC6A3ADAMTS5 | |
| Hydrochloric Acid SCHEMBL5631596 | 0.99 | RAD52 (0.48) | RAD52SLC6A2SLC6A4SLC6A3ADAMTS5 | |
| Hydrochloric Acid SCHEMBL5631590 | 0.99 | RAD52 (0.48) | RAD52SLC6A2SLC6A4SLC6A3ADAMTS5 | |
| Hydrochloric Acid SCHEMBL17871204 | 0.99 | RAD52 (0.48) | RAD52SLC6A2SLC6A4SLC6A3ADAMTS5 | |
| SCHEMBL5630986 | 0.89 | RAD52 (0.46) | RAD52SLC6A2SLC6A4SLC6A3ADAMTS5 | |
| SCHEMBL5633042 | 0.89 | RAD52 (0.46) | RAD52SLC6A2SLC6A4SLC6A3ADAMTS5 | |
| SCHEMBL30609666 | 0.89 | RAD52 (0.46) | RAD52SLC6A2SLC6A4SLC6A3ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | claimed |
| CN-1809545-A | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5HT2c | ARENA PHARM INC (US) | 2006-07-26 | — | — | CN | claimed |
| US-20210052600-A1 | THERAPEUTIC AGENTS FOR STRESS URINARY INCONTINENCE AND INCOTINENCE OF FECES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-02-25 | — | — | US | disclosed |
| EP-3733204-A1 | THERAPEUTIC AGENT FOR STRESS URINARY INCONTINENCE AND FECAL INCONTINENCE | Takeda Pharmaceutical Company Limited (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| EP-1644347-A1 | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT sb 2C /sb RECEPTOR ASSOCIATED DISEASES | Arena Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005016902-A1 | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | HTR2C, HTR2A, HTR5A | RAD52 1733/4885SLC6A2 60/4885SLC6A4 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.